Cart (0 Items)
Your cart is currently empty.
View ProductsSize | 100ug |
---|---|
Brand | Arovia |
Product type | Recombinant Proteins |
Product name | Recombinant CDV F/Fusion glycoprotein F0 Protein, N-His |
---|---|
Origin species | Canine distemper virus (strain Onderstepoort) (CDV) |
Expression system | Prokaryotic expression |
Molecular weight | 41.85 kDa |
Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
Form | Liquid |
Delivery condition | Dry Ice |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
Brand | Arovia |
Host species | Escherichia coli (E.coli) |
Fragment Type | Gly246-Ser608 |
Aliases /Synonyms | Fusion glycoprotein F0, Fusion glycoprotein F2, Fusion glycoprotein F1, F, Canine distemper virus (strain Onderstepoort) (CDV) |
Reference | YVV26501 |
Note | For research use only. |
Recombinant CDV F/Fusion glycoprotein F0 protein is a highly specialized protein that plays a crucial role in the pathogenesis of canine distemper virus (CDV). This recombinant protein is produced through genetic engineering techniques, making it a powerful tool in the study of CDV and its potential as a therapeutic target. In this article, we will explore the structure, activity, and applications of this important protein.
The recombinant CDV F/Fusion glycoprotein F0 protein is a type I transmembrane protein, meaning it spans the membrane of the cell once. It is composed of three distinct regions: the cytoplasmic tail, the transmembrane domain, and the ectodomain. The cytoplasmic tail is responsible for the intracellular signaling and trafficking of the protein, while the transmembrane domain anchors it to the cell membrane. The ectodomain is the largest portion of the protein and is responsible for its functional activity.
The ectodomain of recombinant CDV F/Fusion glycoprotein F0 protein is further divided into two subunits, F1 and F2. F1 is the larger subunit and is responsible for receptor binding, fusion, and viral entry. F2 is the smaller subunit and is involved in the fusion process. These two subunits work together to facilitate the fusion of the viral envelope with the host cell membrane, allowing the virus to enter the cell and initiate infection.
The primary function of recombinant CDV F/Fusion glycoprotein F0 protein is to facilitate viral entry into host cells. This is achieved through its ability to bind to specific receptors on the surface of host cells, leading to fusion of the viral envelope with the cell membrane. This fusion process is essential for the virus to enter the cell and initiate infection.
In addition to its role in viral entry, recombinant CDV F/Fusion glycoprotein F0 protein also plays a crucial role in the pathogenesis of CDV. It has been shown to induce cell-cell fusion, leading to the formation of multinucleated giant cells, which are a hallmark of CDV infection. This fusion process also contributes to the spread of the virus throughout the body and the development of clinical symptoms.
Recombinant CDV F/Fusion glycoprotein F0 protein has a wide range of applications in the study of CDV and its potential as a therapeutic target. One of the most significant applications is in the development of diagnostic tools for CDV. The recombinant protein can be used to develop highly sensitive and specific tests for the detection of CDV infection, aiding in early diagnosis and treatment.
Another important application of recombinant CDV F/Fusion glycoprotein F0 protein is in the development of vaccines against CDV. The protein has been shown to be a potent immunogen, capable of inducing a strong immune response in animals. This makes it an ideal candidate for inclusion in CDV vaccines, which can help prevent the spread of the virus and protect animals from infection.
Furthermore, recombinant CDV F/Fusion glycoprotein F0 protein has also been investigated as a potential therapeutic target for the treatment of CDV infection. By targeting this protein, it may be possible to inhibit viral entry and prevent the spread of the virus within the body. This could potentially lead to the development of new antiviral drugs for the treatment of CDV.
In conclusion, recombinant CDV F/Fusion glycoprotein F0 protein is a crucial component of CDV and plays a significant role in viral entry and pathogenesis. Its unique structure and activity make it a valuable tool in the study of CDV
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Your cart is currently empty.
View Products
Reviews
There are no reviews yet.